Publications

  1. Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, Walker A, Larson RA, Roboz GJ. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022 Jun 28; 6 (12):3812-3820
    View PubMed
  2. Ehret CJ, Almodallal Y, Le-Rademacher JG, Martin NA, Moynagh MR, Rajotia A, Jatoi A. Hiccups in patients with cancer: a multi-site, single-institution study of etiology, severity, complications, interventions, and outcomes. BMC Cancer. 2022 Jun 15; 22 (1):659 Epub 2022 June 15
    View PubMed
  3. Peil E, Williams GR, Rugo H, Woyach JA, Jatoi A, Le-Rademacher JG. Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. J Geriatr Oncol. 2022 May; 13 (4):526-529 Epub 2021 Dec 15
    View PubMed
  4. Ehret CJ, Le-Rademacher JG, Martin N, Jatoi A. Olanzapine for cisplatin-induced hiccups: observations from a 338-patient study. Ann Palliat Med. 2022 Apr 24 [Epub ahead of print]
    View PubMed
  5. Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022 Mar 17; 139 (11):1684-1693
    View PubMed
  6. Zahrieh D, Kandler BW, Le-Rademacher J. Symbolic two-step method compared with single-step methods to model the center-mean outcome in cluster randomized trials. Contemp Clin Trials. 2022 Mar; 114:106684 Epub 2022 Jan 18
    View PubMed
  7. Brazauskas R, Jatoi A, Le-Rademacher JG. A Cautionary Tale: Grouping Patients on Late Events. Mayo Clin Proc. 2022 Mar; 97 (3):449-453 Epub 2022 Feb 05
    View PubMed
  8. Zahrieh D, Satele D, Smith EML, Loprinzi CL, Le-Rademacher J. Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months. Cancers (Basel). 2022 Feb 25; 14 (5)
    View PubMed
  9. Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD. Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Feb 1; 8 (2):259-267
    View PubMed
  10. VanderWalde NA, Dockter T, Wakefield DV, Satele D, Sloan J, Jagsi R, Lichtman SM, Freedman RA, Lafky JM, Muss H, Cohen HJ, Le-Rademacher J, Jatoi A. Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736). J Geriatr Oncol. 2022 Jan; 13 (1):20-26 Epub 2021 Aug 04
    View PubMed
  11. Ehret CJ, Le-Rademacher JG, Martin N, Jatoi A. Dexamethasone and hiccups: a 2000-patient, telephone-based study. BMJ Support Palliat Care. 2021 Dec 13 [Epub ahead of print]
    View PubMed
  12. Duong Q, Mandrekar SJ, Winham SJ, Cook K, Jatoi A, Le-Rademacher JG. Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials. J Cancer Educ. 2021 Dec; 36 (6):1248-1252
    View PubMed
  13. Hertz DL, Dockter TJ, Satele DV, Loprinzi CL, Le-Rademacher J. Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912). Support Care Cancer. 2021 Dec; 29 (12):7855-7863 Epub 2021 June 27
    View PubMed
  14. Almodallal Y, Cook K, Lammert LM, Lee M, Le-Rademacher JG, Jatoi A. Can older patients adopt and maintain a ketogenic diet? An observational study in support of clinical trials in older patients. Medicine (Baltimore). 2021 Nov 24; 100 (47):e28033
    View PubMed
  15. He J, Perez DG, Le-Rademacher JL, Dodge A, Enck P, Loprinzi CL, Zahrieh D. Does the placebo effect on hot flashes depend on the placebo dose? Support Care Cancer. 2021 Nov; 29 (11):6741-6749 Epub 2021 May 11
    View PubMed
  16. Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021 Nov; 29 (11):7129-7130
    View PubMed
  17. Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer. 2021 Oct 15; 127 (20):3801-3808 Epub 2021 Aug 10
    View PubMed
  18. Almodallal Y, Duong Q, Satele D, Novotny P, Cook KD, Chauhan C, Daiss MK, Le-Rademacher J, Looker S, Martin N, Smestad MF, Winham SJ, Mandrekar SJ, Jatoi A. Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. JCO Oncol Pract. 2021 Oct; 17 (10):e1460-e1472 Epub 2021 June 14
    View PubMed
  19. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 Jul; 26 (7):610-618 Epub 2021 Mar 06
    View PubMed
  20. Le-Rademacher J, Wang X. Time-To-Event Data: An Overview and Analysis Considerations. J Thorac Oncol. 2021 Jul; 16 (7):1067-1074 Epub 2021 Apr 19
    View PubMed
  21. Almodallal Y, Le-Rademacher JG, Cook KD, Yadav S, Singh AB, Lee M, Lammert LM, Jatoi A. Observations with alpelisib in older patients (>/= 65 year of age) with breast cancer in a non-clinical trial setting. Breast Cancer Res Treat. 2021 Jul; 188 (1):15-20 Epub 2021 June 12
    View PubMed
  22. Childs DS, Le-Rademacher JG, McMurray R, Bendel M, O'Neill C, Smith TJ, Loprinzi CL. Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis. J Pain Symptom Manage. 2021 Jun; 61 (6):1247-1253 Epub 2020 Nov 27
    View PubMed
  23. Maggiore RJ, Zahrieh D, McMurray RP, Feliciano JL, Samson P, Mohindra P, Chen H, Wong ML, Lafky JM, Jatoi A, Le-Rademacher JG. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). J Geriatr Oncol. 2021 May; 12 (4):563-571 Epub 2020 Sept 16
    View PubMed
  24. Matsui S, Le-Rademacher J, Mandrekar SJ. Statistical Models in Clinical Studies. J Thorac Oncol. 2021 May; 16 (5):734-739 Epub 2021 Feb 26
    View PubMed
  25. Guerard E, Dodge AB, Le-Rademacher JG, Kemeny MM, Ojelabi M, Sedrak MS, Hopkins J, Shahrokni A, Harlos E, Muss H, Cohen HJ, Lafky J, Sloan J, Jatoi A, Hurria A. Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603). JCO Clin Cancer Inform. 2021 Apr; 5:435-441
    View PubMed
  26. Martin NA, Harlos ES, Cook KD, O'Connor JM, Dodge A, Guerard E, Lafky JM, Jatoi A, Le-Rademacher JG. How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902). JCO Clin Cancer Inform. 2021 Apr; 5:442-449
    View PubMed
  27. Adjei AA, Lopez CL, Schaid DJ, Sloan JA, Le-Rademacher JG, Loprinzi CL, Norman AD, Olson JE, Couch FJ, Beutler AS, Vachon CM, Ruddy KJ. Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. Cancers (Basel). 2021 Mar 3; 13 (5) Epub 2021 Mar 03
    View PubMed
  28. Wang X, Piantadosi S, Le-Rademacher J, Mandrekar SJ. Statistical Considerations for Subgroup Analyses. J Thorac Oncol. 2021 Mar; 16 (3):375-380 Epub 2020 Dec 26
    View PubMed
  29. Adjei AA, Lopez CL, Schaid DJ, Sloan JA, Le-Rademacher JG, Loprinzi CL, Norman AD, Olson JE, Couch FJ, Beutler AS, Vachon CM, Ruddy KJ. Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach. Cancers (Basel). 2021 Feb 10; 13 (4)
    View PubMed
  30. Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021 Feb; 29 (2):833-840 Epub 2020 June 04
    View PubMed
  31. Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2021 Feb; 144:37-44 Epub 2020 Dec 02
    View PubMed
  32. Naughton MJ, Liu H, Seisler DK, Le-Rademacher J, Armer JM, Oliveri JM, Sloan JA, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C, Paskett ED. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 Jan 15; 127 (2):300-309 Epub 2020 Oct 20
    View PubMed
  33. Paskett ED, Le-Rademacher J, Oliveri JM, Liu H, Seisler DK, Sloan JA, Armer JM, Naughton MJ, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 Jan 15; 127 (2):291-299 Epub 2020 Oct 20
    View PubMed
  34. Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, Wildes TM, Le-Rademacher JG, Kimmick GG, Tew WP, George K, Padam S, Liu J, Wong AR, Lynch A, Djulbegovic B, Mohile SG, Dale W, Cancer and Aging Research Group (CARG). Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin. 2021 Jan; 71 (1):78-92 Epub 2020 Oct 01
    View PubMed
  35. Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Support Care Cancer. 2021 Jan; 29 (1):387-396 Epub 2020 May 06
    View PubMed
  36. Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR. The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. Blood Lymphat Cancer. 2021; 11:1-9 Epub 2021 Jan 22
    View PubMed
  37. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Front Immunol. 2021; 12:700045 Epub 2021 Sept 03
    View PubMed
  38. Le-Rademacher J, Lopez C, Wolfe E, Foster NR, Mandrekar SJ, Wang X, Kumar R, Adjei A, Jatoi A. Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. J Cachexia Sarcopenia Muscle. 2020 Dec; 11 (6):1501-1508 Epub 2020 Sept 17
    View PubMed
  39. Le-Rademacher JG, Jatoi A. Editorial: What about weight? Advocating for simplicity in cancer cachexia trials. Curr Opin Support Palliat Care 2020 Dec; 14 (4):302-303
    View PubMed
  40. Almodallal Y, Lee MK, Le-Rademacher JG, Smith CJ, Carroll JL, Robinson SI, Jatoi A. Non-Squamous, Non-Basal Cell Cancers of the Skin: Exploring Associations Between Site of Disease and Depression. Am J Hosp Palliat Care. 2020 Nov 15; 1049909120969605 [Epub ahead of print]
    View PubMed
  41. Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, Mandrekar SJ. Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. Cancers (Basel). 2020 Nov 4; 12 (11) Epub 2020 Nov 04
    View PubMed
  42. Ou FS, Le-Rademacher JG, Ballman KV, Adjei AA, Mandrekar SJ. Guidelines for Statistical Reporting in Medical Journals. J Thorac Oncol. 2020 Nov; 15 (11):1722-1726 Epub 2020 Aug 25
    View PubMed
  43. Loprinzi CL, Le-Rademacher JG, Navari RM. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply. JAMA Oncol 2020 Nov 1; 6 (11):1812-1813
    View PubMed
  44. Dahlberg SE, Korn EL, Le-Rademacher J, Mandrekar SJ. Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. J Thorac Oncol. 2020 Sep; 15 (9):1406-1408 Epub 2020 June 21
    View PubMed
  45. Zahrieh D, Le-Rademacher J. Sample size planning in the design and analysis of cluster randomized trials using the symbolic two-step method. Contemp Clin Trials Commun. 2020 Sep; 19:100609 Epub 2020 July 08
    View PubMed
  46. An MW, Duong Q, Le-Rademacher J, Mandrekar SJ. Principles of Good Clinical Trial Design. J Thorac Oncol. 2020 Aug; 15 (8):1277-1280 Epub 2020 May 15
    View PubMed
  47. Eaton A, Therneau T, Le-Rademacher J. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations. Clin Trials. 2020 Jun; 17 (3):285-294 Epub 2020 Feb 17
    View PubMed
  48. Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 Jun 1; 6 (6):895-899
    View PubMed
  49. Salgado TM, Liu J, Reed HL, Quinn CS, Syverson JG, Le-Rademacher J, Lopez CL, Beutler AS, Loprinzi CL, Vangipuram K, Smith EML, Henry NL, Farris KB, Hertz DL. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study. Breast. 2020 Jun; 51:21-28 Epub 2020 Mar 03
    View PubMed
  50. Majhail NS, Mau LW, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, LeMaistre CF, Loberiza F, Parsons SK, Repaczki-Jones R, Robinett P, Douglas Rizzo J, Murphy E, Logan B, Le-Rademacher J. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant. 2020 May; 55 (5):906-917 Epub 2019 Nov 18
    View PubMed
  51. Le-Rademacher JG, Lopez CL, Kanwar R, Major-Elechi B, Abyzov A, Banck MS, Therneau TM, Sloan JA, Loprinzi CL, Beutler AS. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. J Neurol Sci. 2020 Apr 15; 411:116687 Epub 2020 Jan 14
    View PubMed
  52. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31.
    View PubMed
  53. Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O'Neill CR, Bendel MA, Beutler A, Lachance DH, Cheville A, Strick DM, Black DF, Tilburt JC, Smith TJ. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020 Mar; 28 (3):1183-1197 Epub 2019 June 17
    View PubMed
  54. McBane RD 2nd, Loprinzi CL, Ashrani A, Lenz CJ, Houghton D, Zemla T, Le-Rademacher JG, Wysokinski WE. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol. 2020 Feb; 104 (2):88-96 Epub 2019 Nov 11
    View PubMed
  55. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb; 18 (2):411-421 Epub 2019 Nov 28
    View PubMed
  56. Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 Jan; 11 (1):107-113 Epub 2019 Oct 24
    View PubMed
  57. Dao D, O'Connor JM, Jatoi A, Ridgeway J, Deering E, Schwecke A, Breitkopf CR, Huston O, Le-Rademacher JG. A qualitative study of healthcare-related experiences of non-smoking women with lung cancer. Support Care Cancer. 2020 Jan; 28 (1):123-130 Epub 2019 Apr 15
    View PubMed
  58. Le-Rademacher JG, Storrick EM, Jatoi A. Remarks on the design and analyses of longitudinal studies for cancer patients with anorexia and weight loss. J Cachexia Sarcopenia Muscle. 2019 Dec; 10 (6):1175-1182 Epub 2019 Aug 20
    View PubMed
  59. Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Dockter T, Tan AD, Beutler A, Loprinzi CL. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. Breast. 2019 Dec; 48:89-97 Epub 2019 Sept 19
    View PubMed
  60. Al-Refaie WB, Decker PA, Ballman KV, Pisters PWT, Posner MC, Hunt KK, Meyers B, Weinberg AD, Nelson H, Newman L, Tan A, Le-Rademacher JG, Hurria A, Jatoi A. Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). Ann Surg Oncol. 2019 Dec; 26 (13):4213-4221 Epub 2019 Oct 11
    View PubMed
  61. Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrozek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 Nov; 33 (11):2599-2609 Epub 2019 May 09
    View PubMed
  62. Vij R, Le-Rademacher J, Laumann K, Hars V, Owzar K, Shore T, Vasu S, Cashen A, Isola L, Shea T, DeMagalhaes-Silverman M, Hurd D, Meehan K, Beardell F, Devine S. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biol Blood Marrow Transplant. 2019 Oct; 25 (10):1984-1992 Epub 2019 June 15
    View PubMed
  63. Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, Le-Rademacher J, Yang JJ. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Support Care Cancer. 2019 Jul; 27 (7):2599-2608 Epub 2018 Nov 20
    View PubMed
  64. Le-Rademacher JG, Rowland K, Atherton PJ, Dakhil C, Sun Z, Tan A, Schmidt L, Nguyen PL, Radecki Breitkopf C, Pittelkow M, Tindall D, Menon S, Jatoi A. Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series. Am J Hosp Palliat Care. 2019 Jun; 36 (6):519-525 Epub 2019 Jan 02
    View PubMed
  65. Dao D, Zemla T, Jatoi A, Freedman RA, Hurria A, Muss H, Cohen HJ, Shulman LN, Citron M, Budman D, McMurray R, Partridge A, Carey L, Sedrak MS, Lafky JM, Le-Rademacher JG. Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). Oncologist. 2019 Jun; 24 (6):e284-e291 Epub 2019 Apr 11
    View PubMed
  66. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40 Epub 2019 Apr 25
    View PubMed
  67. Le-Rademacher JG, Storrick EM, Jatoi A, Mandrekar SJ. Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials. Mayo Clin Proc Innov Qual Outcomes. 2019 Jun; 3 (2):176-182 Epub 2019 May 27
    View PubMed
  68. Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019 May; 67 (5):920-927 Epub 2018 Aug 26
    View PubMed
  69. Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Copur MS, Biggs D, Ramaswamy B, Lafky JM, Jatoi A. Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. Oncologist. 2019 May; 24 (5):617-623 Epub 2018 Nov 08
    View PubMed
  70. Zahrieh D, Alexander A, Fruth B, Tan AD, Le-Rademacher J, Warsame R, Croghan K, Sloan JA. A Case Management System for Integrating Patient-reported Outcome Assessment in Clinical Practice: The Beacon Tool. Med Care. 2019 May; 57 Suppl 5 Suppl 1:S73-S79
    View PubMed
  71. Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019 Apr 16; 321 (15):1481-1490
    View PubMed
  72. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019 Mar 26; 3 (6):875-883
    View PubMed
  73. Childs DS, Looker S, Le-Rademacher J, Ridgeway JL, Breitkopf CR, Jatoi A. What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. Support Care Cancer. 2019 Jan; 27 (1):249-255 Epub 2018 June 25
    View PubMed
  74. Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol. 2018 Nov; 13 (11):1625-1637 Epub 2018 Sept 04
    View PubMed
  75. Le-Rademacher JG, Peterson RA, Therneau TM, Sanford BL, Stone RM, Mandrekar SJ. Application of multi-state models in cancer clinical trials. Clin Trials. 2018 Oct; 15 (5):489-498 Epub 2018 July 23
    View PubMed
  76. Feliciano JL, Le-Rademacher JG, Gajra A, Edelman MJ, Zemla T, McMurray R, Chen H, Hurria A, Muss H, Cohen HJ, Lilenbaum R, Jatoi A. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol. 2018 Sep; 9 (5):501-506 Epub 2018 May 27
    View PubMed
  77. Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2018 Aug; 24 (8):1651-1656 Epub 2018 May 09
    View PubMed
  78. Gajra A, Zemla TJ, Jatoi A, Feliciano JL, Wong ML, Chen H, Maggiore R, McMurray RP, Hurria A, Muss HB, Cohen HJ, Lafky J, Edelman MJ, Lilenbaum R, Le-Rademacher JG. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). J Thorac Oncol. 2018 Jul; 13 (7):996-1003 Epub 2018 Mar 30
    View PubMed
  79. Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017 Nov; 25 (11):3537-3544 Epub 2017 June 20
    View PubMed
  80. Foster JC, Le-Rademacher JG, Feliciano JL, Gajra A, Seisler DK, DeMatteo R, Lafky JM, Hurria A, Muss HB, Cohen HJ, Jatoi A. Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer. 2017 Nov 1; 123 (21):4193-4198 Epub 2017 July 12
    View PubMed
  81. Malogolowkin MH, Hemmer MT, Le-Rademacher J, Hale GA, Mehta PA, Smith AR, Kitko C, Abraham A, Abdel-Azim H, Dandoy C, Angel Diaz M, Gale RP, Guilcher G, Hayashi R, Jodele S, Kasow KA, MacMillian ML, Thakar M, Wirk BM, Woolfrey A, Thiel EL. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2017 Nov; 52 (11):1549-1555 Epub 2017 Sept 04
    View PubMed
  82. McBane RD, McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thromb Haemost. 2017 Oct 5; 117 (10):1952-1961 Epub 2017 Aug 24
    View PubMed
  83. Le-Rademacher JG, Crawford J, Evans WJ, Jatoi A. Overcoming obstacles in the design of cancer anorexia/weight loss trials. Crit Rev Oncol Hematol. 2017 Sep; 117:30-37 Epub 2017 June 24
    View PubMed
  84. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
    View PubMed
  85. Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol. 2017 Jun 1; 28 (6):1183-1190
    View PubMed
  86. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10; 35 (11):1154-1161 Epub 2017 Feb 13
    View PubMed
  87. Wingard JR, Wood WA, Martens M, Le-Rademacher J, Logan B, Knight JM, Jacobsen PB, Jim H, Majhail NS, Syrjala K, Rizzo JD, Lee SJ. Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). Biol Blood Marrow Transplant. 2017 Jan; 23 (1):161-164 Epub 2016 Oct 11
    View PubMed
  88. Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, Horowitz MM, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant. 2016 Dec; 22 (12):2256-2263 Epub 2016 Aug 23
    View PubMed
  89. Brazauskas R, Le-Rademacher J. Methods for generating paired competing risks data. Comput Methods Programs Biomed. 2016 Oct; 135:199-207 Epub 2016 July 25
    View PubMed
  90. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Oct; 22 (10):1893-1899 Epub 2016 Aug 02
    View PubMed
  91. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25; 128 (8):1050-8 Epub 2016 June 13
    View PubMed
  92. Le-Rademacher J. A center-level approach to estimating the effect of center characteristics on center outcomes. Advances in the Mathematical Sciences: Research from the 2015 Association for Women in Mathematics Symposium.2016 Aug;301-321.
  93. Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Aug; 22: (8)1424-30.
    View PubMed
  94. Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer. 2016 Jul 15; 122 (14):2197-205 Epub 2016 May 03
    View PubMed
  95. Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant. 2016 Jul; 22: (7)1197-205.
    View PubMed
  96. Le-Rademacher J, Billard L. Principal Component Analysis for Histogram-valued Data Advances in Data Analysis and Classification.2016 May 26;Epub:1 - 25.
  97. Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016 Apr; 14: (4)141-7.
    View PubMed
  98. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Dec; 21 (12):2154-2159 Epub 2015 Aug 29
    View PubMed
  99. Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2015 Oct 06.
    View PubMed
  100. Ayas M, Eapen M, Le-Rademacher J, Carreras J, Abdel-Azim H, Alter BP, Anderlini P, Battiwalla M, Bierings M, Buchbinder DK, Bonfim C, Camitta BM, Fasth AL, Gale RP, Lee MA, Lund TC, Myers KC, Olsson RF, Page KM, Prestidge TD, Radhi M, Shah AJ, Schultz KR, Wirk B, Wagner JE, Deeg HJ. Second allogeneic hematopoietic cell transplantation for patients with Fanconi Anemia and bone marrow failure. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1790-5.
  101. Orchard PJ, Fasth AL, Le-Rademacher J, He W, Boelens JJ, Horwitz EM, Al-Seraihy A, Ayas M, Bonfim CM, Boulad F, Lund T, Buchbinder DK, Kapoor N, O'Brien TA, Perez MA, Veys PA, Eapen M. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood 9. 2015 Jul 9; 126(2):270-6.
  102. Majhail NS, Mau LW, Chitphakdithai P, Payton T, Eckrich M, Joffe S, Lee S, LeMaistre CF, Le-Rademacher J, Loberiza F, Logan B, Parsons SK, Repaczki-Jones R, Robinett P, Rizzo JD. National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1308-14.
  103. Hong S, Le-Rademacher J, Artz A, McCarthy P, Logan B, Pasquini M. Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders. Bone Marrow Transplant. 2015 Mar; 50(3):367-74.
  104. Kim SY, Le-Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014 Dec; 99(12):1868-75.
  105. Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail SJ. Exercise and stress management training prior to hemtopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1530-6.
  106. Li J, Le-Rademacher J, Zhang MJ. Weighted comparison of two cumulative incidence functions with R-CIFsmry package. Comput Methods Programs Biomed. 2014 Oct; 116(3):205-14.
  107. Saber W, Le-Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, DiFronzo N, Appelbaum F, Horowitz MM, Nakamura R, Cutler CS. Multi-Center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high risk myelodysplastic syndrome Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design and Methods. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1566-1572.
  108. Torlen J, Ringden O, Le-Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M. Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1418-25.
  109. Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB, Szer J, Rowe JM, Weisdorf DJ, Tallman MS. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant. 2014 Jul; 20(7):1021-5.
  110. Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014 Mar; 49 (3):416-21 Epub 2013 Nov 25
    View PubMed
  111. Kosmelj K, Le-Rademacher J, Billard L. Symbolic covariance matrix for interval-valued variables and its application to principal component analysis: a Case Study. Metodoloski Zvezki - Advances in Methodology and Statistics. 2014; 11(1):1-20.
  112. Bredeson C, Le-Rademacher J, Kato K, DiPersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 5. 2013 Dec 5; 122(24):3871-8.
  113. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 1; 31: (25)3100-9.
    View PubMed
  114. Billard L, Le-Rademacher J. Symbolic Principal Components for Interval-Valued Data. Revue des Nouvelles Technologies de l'Information.2013;25:31 - 40.
  115. Le-Rademacher J, Brazauskas R. Inference for Paired Survival Data Handbook of Survival Analysis. 2013; 615-632.
  116. Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, Wraith E, Cavazzana-Calvo M, Rovelli A, Fischer A, Tolar J, Prasad VK, Escolar M, Gluckman E, O'Meara A, Orchard PJ, Veys P, Eapen M, Kurtzberg J, Rocha V, Le-Rademacher J, Eurocord//Inborn Errors Working Party of European Blood and Marrow Transplant group//Duke University Blood and Marrow Transplantation Program//Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013 May 9; 121: (19)3981-7.
    View PubMed
  117. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19: (5)760-6.
    View PubMed
  118. Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, LeRademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, Camitta BM, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, MacMillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fasth AL, Guinan EC, Horn BN, Lewis VA, Slavin S, Stepensky P, Bierings M, Gale RP. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol. 2013 May 1; 31(13):1669-76. Epub 2013 Apr 1
    View PubMed
  119. Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood. 2013 Mar 28; 121(13):2567-73.
  120. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, Cutler C, Delaney C, Kan F, Isola L, Karanes C, Laughlin MJ, Wagner JE, Shpall EJ. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013 Jan 31; 121(5):752-8.
  121. Le-Rademacher J, Billard L. Principal component histograms from interval-valued observations. Computational Statistics. 2013; 28:2117-2138.
  122. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120: (20)4256-62.
    View PubMed
  123. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant. 2012 Jul; 18: (7)1036-1043.e1.
    View PubMed
  124. Le-Rademacher J, Billard L. Symbolic-covariance principal component analysis and visualization for interval-valued data. Journal of Computational and Graphical Statistics. 2012 Jul; 21(2):413-432.
  125. Billard L, Le-Rademacher J. Principal component analysis for interval data. Wiley Interdisciplinary Reviews: Computational Statistics. 2012:535-540.
  126. Kamani NR, Kumar S, Hassebroek A, Eapen M, Le-Rademacher J, Casper J, Cowan M, Sanchez de Toledo J, Ferster A, Szabolcs P, Wingard JR, Horwitz E, Filipovich AH. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the CIBMTR. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1783-9.
  127. Eapen M, Le-Rademacher J, Antin J, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JC, Deeg HJ. Effect of stem cell source on outcomes after adult unrelated donor transplantation in severe aplastic anemia. Blood 1. 2011 Sep 1; 118(9):2618-21.
  128. Soiffer RJ, Le-Rademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen M. Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood. 2011 Jun 23; 117(25):6936-70.
  129. Le-Rademacher J, Billard L. Likelihood functions and some maximum likelihood estimators for symbolic data. Journal of Statistical Planning and Inference. 2011 April; 141(4):1593-1602.
  130. Datta S, Le-Rademacher J, Datta S. Predicting patient survival from microarray data by accelerated failure time modeling using partial least squares and LASSO. Biometrics. 2007 Mar; 63 (1):259-71
    View PubMed